Cumberland Pharmaceuticals Inc.: 10-Q filed 2022-11-14

Name: Cumberland Pharmaceuticals Inc.: 10-Q filed 2022-11-14
Creator: Cumberland Pharmaceuticals Inc.

What Cumberland Pharmaceuticals Inc. reported in its quarterly report filed 2022-11-14 (fiscal Q3 2022): 42 published measures, 123 facts as tagged in accession 0001628280-22-029906.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-11-14
Fiscal period: fiscal Q3 2022
Accession: 0001628280-22-029906 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Cumberland Pharmaceuticals Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-09-30	90,776,553	USD
At 2021-12-31	84,459,798	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-09-30	52,285,431	USD
At 2021-12-31	41,857,820	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2022-09-30	38,764,263	USD
At 2021-12-31	42,814,306	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2022-09-30	19,541,538	USD
At 2021-12-31	27,040,816	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-408,639	USD	92
2022-01-01 to 2022-09-30	-3,129,512	USD	273
2021-07-01 to 2021-09-30	-1,055,278	USD	92
2021-01-01 to 2021-09-30	340,110	USD	273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	4,815,365	USD	273
2021-01-01 to 2021-09-30	4,382,763	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	255,676	USD	273
2021-01-01 to 2021-09-30	94,485	USD	273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	11,413,072	USD	92
2022-01-01 to 2022-09-30	32,887,269	USD	273
2021-07-01 to 2021-09-30	8,072,540	USD	92
2021-01-01 to 2021-09-30	27,665,182	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	719,041	USD	273
2021-01-01 to 2021-09-30	-2,818,230	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-13,033,684	USD	273
2021-01-01 to 2021-09-30	-475,098	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-09-30	-8,768,112	USD
At 2021-12-31	-5,638,600	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	14,477,478	shares	92
2022-01-01 to 2022-09-30	14,618,975	shares	273
2021-07-01 to 2021-09-30	14,880,887	shares	92
2021-01-01 to 2021-09-30	14,939,919	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	14,477,478	shares	92
2022-01-01 to 2022-09-30	14,618,975	shares	273
2021-07-01 to 2021-09-30	14,880,887	shares	92
2021-01-01 to 2021-09-30	15,139,904	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-0.03	USD/shares	92
2022-01-01 to 2022-09-30	-0.21	USD/shares	273
2021-07-01 to 2021-09-30	-0.07	USD/shares	92
2021-01-01 to 2021-09-30	0.02	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-0.03	USD/shares	92
2022-01-01 to 2022-09-30	-0.21	USD/shares	273
2021-07-01 to 2021-09-30	-0.07	USD/shares	92
2021-01-01 to 2021-09-30	0.02	USD/shares	273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	6,900	USD	92
2022-01-01 to 2022-09-30	20,700	USD	273
2021-07-01 to 2021-09-30	7,458	USD	92
2021-01-01 to 2021-09-30	22,375	USD	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2022-09-30	490,826	USD
At 2021-12-31	442,635	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	320,598	USD	273
2021-01-01 to 2021-09-30	517,081	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-288,588	USD	92
2022-01-01 to 2022-09-30	-3,427,125	USD	273
2021-07-01 to 2021-09-30	-1,563,395	USD	92
2021-01-01 to 2021-09-30	-3,323,424	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-09-30	49,160,606	USD
At 2021-12-31	45,688,013	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	149,340	USD	92
2022-01-01 to 2022-09-30	406,539	USD	273
2021-07-01 to 2021-09-30	20,021	USD	92
2021-01-01 to 2021-09-30	70,297	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-09-30	25,306,223	USD
At 2021-12-31	19,278,960	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2022-09-30	11,510,756	USD
At 2021-12-31	9,640,980	USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

Period	Value	Unit	Days
At 2022-09-30	1,932,876	USD
At 2021-12-31	882,000	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2022-09-30	29,048,043	USD
At 2021-12-31	23,954,475	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2022-09-30	15,232,697	USD
At 2021-12-31	6,877,346	USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	863,383	USD	273
2021-01-01 to 2021-09-30	1,025,657	USD	273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2022-09-30	10,647,529	USD
At 2021-12-31	8,429,882	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	1,714,254	USD	92
2022-01-01 to 2022-09-30	5,283,083	USD	273
2021-07-01 to 2021-09-30	1,453,873	USD	92
2021-01-01 to 2021-09-30	4,071,638	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-09-30	14,436,583	shares
At 2021-12-31	14,742,754	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2022-09-30	19,541,538	USD
At 2021-12-31	27,040,816	USD
At 2021-09-30	25,843,231	USD
At 2020-12-31	24,753,796	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit
At 2022-09-30	38,491,122	USD
At 2022-06-30	39,204,292	USD
At 2022-03-31	40,793,403	USD
At 2021-12-31	42,601,978	USD
At 2021-09-30	46,646,265	USD
At 2021-06-30	47,808,407	USD
At 2021-03-31	46,877,927	USD
At 2020-12-31	46,873,394	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2022-09-30	219,850	USD
At 2021-12-31	1,024,200	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2022-09-30	229,605	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2022-09-30	2,426,996	USD
At 2021-12-31	3,419,908	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-416,326	USD	92
2022-01-01 to 2022-09-30	-3,169,625	USD	273
2021-07-01 to 2021-09-30	-1,576,022	USD	92
2021-01-01 to 2021-09-30	-1,187,170	USD	273

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-423,226	USD	92
2022-01-01 to 2022-09-30	-3,190,325	USD	273
2022-04-01 to 2022-06-30	-1,364,666	USD	91
2022-01-01 to 2022-03-31	-1,402,433	USD	90
2021-07-01 to 2021-09-30	-1,086,693	USD	92
2021-01-01 to 2021-09-30	281,459	USD	273
2021-04-01 to 2021-06-30	1,223,491	USD	91
2021-01-01 to 2021-03-31	144,661	USD	90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	2,166,118	USD	92
2022-01-01 to 2022-09-30	6,672,442	USD	273
2021-07-01 to 2021-09-30	2,039,799	USD	92
2021-01-01 to 2021-09-30	6,367,438	USD	273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	4,816,630	USD	273
2021-01-01 to 2021-09-30	3,529,245	USD	273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	1,486,448	USD	92
2022-01-01 to 2022-09-30	4,609,146	USD	273
2021-07-01 to 2021-09-30	1,013,948	USD	92
2021-01-01 to 2021-09-30	3,354,080	USD	273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	8,184,656	USD	273
2021-01-01 to 2021-09-30	-2,527,183	USD	273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-1,338,881	USD	273
2021-01-01 to 2021-09-30	-2,555,393	USD	273

Inspect the source

Entity: Cumberland Pharmaceuticals Inc. / CIK 0001087294
Captured: 2026-09-20T05:21:29.619Z
SEC response SHA-256: b37ed2fef35db1cde0c40b2233eb97cf370fc96d41a5c7d61b6a5a76a296e4a0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001087294.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))